摘要
目的探讨血脂蛋白相关磷脂酶A2(Lp-PLA2)水平对冠心病的诊断价值。方法方便收集2019年9—11月因拟诊冠心病住院的173例患者资料,根据CAG检查结果分为冠心病组和对照组。冠心病组121例根据主要冠状动脉病变支数分为单支病变、双支病变和三支病变组,对照组52例患者冠状动脉造影检查结果未达到诊断标准。测定各组患者血清Lp-PLA2水平并进行比较。结果冠心病组和对照组Lp-PLA2水平分别为(271.09±60.27)ng/mL、(190.55±37.03)ng/mL,差异有统计学意义(P<0.001)。冠心病双支、三支病变组分别为(287.94±46.26)ng/mL、(306.43±58.47)ng/mL,均高于单支冠脉病变组[(236.37±52.64)ng/mL],差异有统计学意义(P<0.001)。Lp-PLA2诊断冠心病的ROC曲线下面积为0.868(95%置信区间为0.814~0.922,P<0.001),以252.27 ng/mL为最佳截断值,敏感性、特异性分别为0.702、0.942。结论Lp-PLA2水平可用于评价冠脉病变的严重程度。
Objective To investigate the diagnostic value of blood lipoprotein-related phospholipase A2(Lp-PLA2)levels in coronary heart disease.Methods The data of 173 patients hospitalized with suspected coronary heart disease from September to November 2019 were conveniently collected.According to the results of CAG examination,they were divided into coronary heart disease group and control group.The 121 patients in the coronary artery disease group were divided into single-vessel disease,double-vessel disease,and three-vessel disease groups according to the number of main coronary artery diseased branches.The 52 patients in the control group did not meet the diagnostic criteria of coronary angiography.The serum Lp-PLA2 levels of patients in each group were measured and compared.Results The levels of Lp-PLA2 in the coronary heart disease group and the control group were(271.09±60.27)ng/mL and(190.55±37.03)ng/mL,respectively,and the difference was statistically significant(P<0.001).The two-vessel and three-vessel disease groups were(287.94±46.26)ng/mL and(306.43±58.47)ng/mL,respectively,which were higher than the single-vessel coronary artery disease group[(236.37±52.64)ng/mL],the difference was statistical significance(P<0.001).The area under the ROC curve of Lp-PLA2 for the diagnosis of coronary heart disease was 0.868(95%confidence interval 0.814-0.922,P<0.001),with 252.27 ng/mL as the best cut-off value,sensitivity and specificity were 0.702 and 0.942,respectively.Conclusion The level of Lp-PLA2 can be used to evaluate the severity of coronary artery disease.
作者
袁丽萍
林卫
卢新兆
黄晓华
YUAN Li-ping;LIN Wei;LU Xin-zhao;HUANG Xiao-hua(Department of Laboratory Medicine,Longyan First Hospital,Fujian Medical University,Longyan,Fujian Province,364000 China)
出处
《中外医疗》
2020年第35期14-16,共3页
China & Foreign Medical Treatment
关键词
脂蛋白相关磷脂酶A2
冠心病
动脉粥样硬化
Lipoprotein-related phospholipase A2
Coronary heart disease
Atherosclerosis
